BriaCell Therapeutics Corp. Files 8-K
Ticker: BCTXZ · Form: 8-K · Filed: Jan 3, 2025 · CIK: 1610820
Sentiment: neutral
Topics: corporate-filing, financial-reporting
Related Tickers: BCTX
TL;DR
BriaCell Therapeutics filed an 8-K on Jan 3, 2025. Old name was Ansell Capital Corp.
AI Summary
BriaCell Therapeutics Corp. filed an 8-K on January 3, 2025, reporting other events and financial statements. The company, previously known as Ansell Capital Corp. until June 13, 2014, is incorporated in British Columbia and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides an update on BriaCell Therapeutics Corp.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing reporting corporate events and financial statements, not indicating any immediate material changes or risks.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- January 3, 2025 (date) — Date of report
- British Columbia (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for BriaCell Therapeutics Corp.?
The filing reports 'Other Events' and 'Financial Statements and Exhibits' as of January 3, 2025.
When did BriaCell Therapeutics Corp. change its name?
The company was formerly known as Ansell Capital Corp. and the date of the name change was June 13, 2014.
In which jurisdiction is BriaCell Therapeutics Corp. incorporated?
BriaCell Therapeutics Corp. is incorporated in British Columbia.
What is the Standard Industrial Classification (SIC) code for BriaCell Therapeutics Corp.?
The SIC code for BriaCell Therapeutics Corp. is 2834, which corresponds to Pharmaceutical Preparations.
What is the principal executive office address for BriaCell Therapeutics Corp.?
The address of the principal executive office is Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1.
Filing Stats: 478 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-01-03 17:00:25
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex99-1.htm (EX-99.1) — 22KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-25-000281.txt ( ) — 294KB
- bctx-20250103.xsd (EX-101.SCH) — 4KB
- bctx-20250103_def.xml (EX-101.DEF) — 29KB
- bctx-20250103_lab.xml (EX-101.LAB) — 36KB
- bctx-20250103_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On January 3, 2025, BriaCell Therapeutics Corp. issued a press release announcing that its 2025 Annual General Meeting of Shareholders (the "Meeting") will be rescheduled from 10:00 am Eastern Time on January 23, 2025 to 9:00 a.m. Eastern Time on February 5, 2025 at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the rescheduled Meeting. The press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Item 9.01 Condensed interim financial statements and Exhibits EXHIBIT INDEX Exhibit No. 99.1 Press Release dated January 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams January 3, 2025 William V. Williams President and Chief Executive Officer